HUE045109T2 - A B-komplementfaktor modulátorai - Google Patents
A B-komplementfaktor modulátoraiInfo
- Publication number
- HUE045109T2 HUE045109T2 HUE14844168A HUE14844168A HUE045109T2 HU E045109 T2 HUE045109 T2 HU E045109T2 HU E14844168 A HUE14844168 A HU E14844168A HU E14844168 A HUE14844168 A HU E14844168A HU E045109 T2 HUE045109 T2 HU E045109T2
- Authority
- HU
- Hungary
- Prior art keywords
- modulators
- complement factor
- complement
- factor
- Prior art date
Links
- 102000003712 Complement factor B Human genes 0.000 title 1
- 108090000056 Complement factor B Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21047—Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361877624P | 2013-09-13 | 2013-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE045109T2 true HUE045109T2 (hu) | 2019-12-30 |
Family
ID=52666522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE14844168A HUE045109T2 (hu) | 2013-09-13 | 2014-09-12 | A B-komplementfaktor modulátorai |
Country Status (33)
Country | Link |
---|---|
US (4) | US20160222389A1 (hu) |
EP (2) | EP3603677A1 (hu) |
JP (3) | JP6666250B2 (hu) |
KR (1) | KR102381790B1 (hu) |
CN (2) | CN112359042A (hu) |
AU (2) | AU2014318580B2 (hu) |
BR (1) | BR112016004671B1 (hu) |
CA (1) | CA2921842A1 (hu) |
CL (2) | CL2016000606A1 (hu) |
CR (1) | CR20160170A (hu) |
DK (1) | DK3043827T3 (hu) |
DO (1) | DOP2016000063A (hu) |
EA (1) | EA035433B1 (hu) |
ES (1) | ES2745758T3 (hu) |
HK (1) | HK1225638A1 (hu) |
HR (1) | HRP20191600T1 (hu) |
HU (1) | HUE045109T2 (hu) |
IL (1) | IL244095A0 (hu) |
LT (1) | LT3043827T (hu) |
MA (1) | MA38959A1 (hu) |
MX (2) | MX371518B (hu) |
MY (1) | MY181251A (hu) |
PE (2) | PE20160500A1 (hu) |
PH (1) | PH12016500443A1 (hu) |
PL (1) | PL3043827T3 (hu) |
PT (1) | PT3043827T (hu) |
RS (1) | RS59252B1 (hu) |
RU (1) | RU2662967C2 (hu) |
SG (2) | SG10201806787VA (hu) |
SI (1) | SI3043827T1 (hu) |
UA (1) | UA119046C2 (hu) |
WO (1) | WO2015038939A2 (hu) |
ZA (1) | ZA201601236B (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2377327T5 (es) | 2006-10-18 | 2020-04-28 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
EP3067421B1 (en) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
CA2921514C (en) | 2013-05-01 | 2023-10-24 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating apolipoprotein c-iii expression |
MY181251A (en) * | 2013-09-13 | 2020-12-21 | Ionis Pharmaceuticals Inc | Modulators of complement factor b |
CN105814205B (zh) * | 2013-12-12 | 2019-11-19 | 阿尔尼拉姆医药品有限公司 | 补体成分iRNA组合物及其使用方法 |
PT3137596T (pt) * | 2014-05-01 | 2019-09-27 | Ionis Pharmaceuticals Inc | Composições e métodos para modulação da expressão do factor b do complemento |
WO2017135397A1 (ja) * | 2016-02-05 | 2017-08-10 | 協和発酵キリン株式会社 | 補体b因子の発現を抑制するアンチセンスオリゴヌクレオチド |
CA3029262A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
TW201827596A (zh) * | 2016-12-23 | 2018-08-01 | 日商協和醱酵麒麟有限公司 | 抑制補體b因子之表現之核酸 |
WO2019027015A1 (ja) * | 2017-08-02 | 2019-02-07 | 協和発酵キリン株式会社 | 核酸複合体 |
SG11202002940QA (en) | 2017-11-01 | 2020-04-29 | Alnylam Pharmaceuticals Inc | Complement component c3 irna compositions and methods of use thereof |
WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
IL297680A (en) * | 2020-04-30 | 2022-12-01 | Alnylam Pharmaceuticals Inc | IRNA compounds complement factor b (cfb) and methods of using them |
KR20230049115A (ko) | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
CN114057692B (zh) | 2020-08-07 | 2023-07-21 | 上海美悦生物科技发展有限公司 | 一种杂环类化合物、其制备方法及用途 |
KR20240035563A (ko) * | 2021-07-17 | 2024-03-15 | 서나오믹스, 인크. | 생성물 및 조성물 |
IL311146A (en) | 2021-09-02 | 2024-04-01 | Silence Therapeutics Gmbh | Nucleic acids to inhibit expression of complement factor B (CFB) in the cell |
AR127477A1 (es) | 2021-10-29 | 2024-01-31 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS |
WO2023129496A2 (en) * | 2021-12-27 | 2023-07-06 | Apellis Pharmaceuticals, Inc. | Rnas for complement inhibition |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
DK0942000T3 (da) | 1989-10-24 | 2004-11-01 | Isis Pharmaceuticals Inc | 2'-modificerede oligonukleotider |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
DE69032425T2 (de) | 1990-05-11 | 1998-11-26 | Microprobe Corp | Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden |
EP0538194B1 (de) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
WO1994014226A1 (en) | 1992-12-14 | 1994-06-23 | Honeywell Inc. | Motor system with individually controlled redundant windings |
EP0691968B1 (en) | 1993-03-30 | 1997-07-16 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
WO2005121371A2 (en) | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
AU1705100A (en) * | 1998-10-09 | 2000-05-01 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
BR0009884A (pt) | 1999-04-21 | 2002-01-08 | American Home Prod | Processos e composições para a inibição da função das sequências de polinucleotìdeos |
CA2372085C (en) | 1999-05-04 | 2009-10-27 | Exiqon A/S | L-ribo-lna analogues |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
JP2003519231A (ja) | 1999-12-30 | 2003-06-17 | カー・ユ・ルーベン・リサーチ・アンド・ディベロップメント | シクロヘキセン核酸 |
EP1499627A2 (en) | 2001-07-03 | 2005-01-26 | ISIS Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
JP4634799B2 (ja) * | 2002-09-13 | 2011-02-16 | ライフ テクノロジーズ コーポレーション | 耐熱性逆転写酵素およびその使用法 |
WO2004044139A2 (en) | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
US7696345B2 (en) | 2002-11-05 | 2010-04-13 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
WO2004103288A2 (en) * | 2003-05-13 | 2004-12-02 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method of preventing recurrent miscarriages |
JP4731324B2 (ja) | 2003-08-28 | 2011-07-20 | 武 今西 | N−o結合性架橋構造型新規人工核酸 |
JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ, インコーポレーテッド | 4’−チオヌクレオシドおよびオリゴマー化合物 |
US7959919B2 (en) * | 2003-11-19 | 2011-06-14 | Novelmed Therapeutics, Inc. | Method of inhibiting factor B-mediated complement activation |
DK1713503T3 (da) | 2004-02-10 | 2013-11-04 | Univ Colorado Regents | Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde |
WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Rna干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
US7919472B2 (en) * | 2004-09-17 | 2011-04-05 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
EP1812569A2 (en) | 2004-11-08 | 2007-08-01 | K.U. Leuven Research and Development | Modified nucleosides for rna interference |
GB0521716D0 (en) * | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ, インコーポレーテッド | 6−修飾された二環式核酸類似体 |
US7547684B2 (en) | 2006-05-11 | 2009-06-16 | Isis Pharmaceuticals, Inc. | 5′-modified bicyclic nucleic acid analogs |
EP2064223B1 (en) * | 2006-09-22 | 2013-04-24 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
CN101589143A (zh) * | 2006-11-27 | 2009-11-25 | Isis药物公司 | 用于治疗高胆固醇血症的方法 |
EP2125852B1 (en) | 2007-02-15 | 2016-04-06 | Ionis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
WO2008106644A2 (en) * | 2007-03-01 | 2008-09-04 | Advanced Vision Therapies, Inc. | Treatment of diseases characterized by inflammation |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
WO2010005310A2 (en) * | 2008-07-10 | 2010-01-14 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Complement antagonists and uses thereof |
EP2361256B1 (en) | 2008-09-24 | 2013-04-10 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acid analogs |
JP6005628B2 (ja) | 2010-04-28 | 2016-10-12 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物 |
AU2011282217B2 (en) * | 2010-07-19 | 2015-12-03 | Ionis Pharmaceuticals, Inc. | Modulation of dystrophia myotonica-protein kinase (DMPK) expression |
JP5951752B2 (ja) * | 2011-04-13 | 2016-07-13 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Ptp1b発現のアンチセンス調節 |
MY181251A (en) | 2013-09-13 | 2020-12-21 | Ionis Pharmaceuticals Inc | Modulators of complement factor b |
PT3137596T (pt) * | 2014-05-01 | 2019-09-27 | Ionis Pharmaceuticals Inc | Composições e métodos para modulação da expressão do factor b do complemento |
-
2014
- 2014-09-12 MY MYPI2016700852A patent/MY181251A/en unknown
- 2014-09-12 ES ES14844168T patent/ES2745758T3/es active Active
- 2014-09-12 WO PCT/US2014/055458 patent/WO2015038939A2/en active Application Filing
- 2014-09-12 PE PE2016000376A patent/PE20160500A1/es unknown
- 2014-09-12 DK DK14844168.6T patent/DK3043827T3/da active
- 2014-09-12 MX MX2016003263A patent/MX371518B/es active IP Right Grant
- 2014-09-12 MA MA38959A patent/MA38959A1/fr unknown
- 2014-09-12 EP EP19182415.0A patent/EP3603677A1/en active Pending
- 2014-09-12 US US15/021,651 patent/US20160222389A1/en not_active Abandoned
- 2014-09-12 CA CA2921842A patent/CA2921842A1/en not_active Abandoned
- 2014-09-12 EP EP14844168.6A patent/EP3043827B1/en active Active
- 2014-09-12 LT LTEP14844168.6T patent/LT3043827T/lt unknown
- 2014-09-12 PE PE2018003111A patent/PE20190354A1/es unknown
- 2014-09-12 CN CN202011263979.3A patent/CN112359042A/zh active Pending
- 2014-09-12 PL PL14844168T patent/PL3043827T3/pl unknown
- 2014-09-12 SI SI201431272T patent/SI3043827T1/sl unknown
- 2014-09-12 SG SG10201806787VA patent/SG10201806787VA/en unknown
- 2014-09-12 AU AU2014318580A patent/AU2014318580B2/en active Active
- 2014-09-12 KR KR1020167009610A patent/KR102381790B1/ko active IP Right Grant
- 2014-09-12 JP JP2016542824A patent/JP6666250B2/ja active Active
- 2014-09-12 CN CN201480056788.6A patent/CN105744959B/zh active Active
- 2014-09-12 RU RU2016113763A patent/RU2662967C2/ru active
- 2014-09-12 HU HUE14844168A patent/HUE045109T2/hu unknown
- 2014-09-12 BR BR112016004671-4A patent/BR112016004671B1/pt active IP Right Grant
- 2014-09-12 RS RSP20191160 patent/RS59252B1/sr unknown
- 2014-09-12 SG SG11201601445XA patent/SG11201601445XA/en unknown
- 2014-09-12 PT PT14844168T patent/PT3043827T/pt unknown
- 2014-09-12 EA EA201690582A patent/EA035433B1/ru unknown
- 2014-12-09 UA UAA201603969A patent/UA119046C2/uk unknown
-
2016
- 2016-02-09 IL IL244095A patent/IL244095A0/en unknown
- 2016-02-22 ZA ZA2016/01236A patent/ZA201601236B/en unknown
- 2016-03-08 PH PH12016500443A patent/PH12016500443A1/en unknown
- 2016-03-11 MX MX2020001258A patent/MX2020001258A/es unknown
- 2016-03-11 DO DO2016000063A patent/DOP2016000063A/es unknown
- 2016-03-14 CL CL2016000606A patent/CL2016000606A1/es unknown
- 2016-04-12 CR CR20160170A patent/CR20160170A/es unknown
- 2016-12-09 HK HK16114054A patent/HK1225638A1/zh unknown
-
2018
- 2018-03-05 US US15/912,386 patent/US20190048351A1/en not_active Abandoned
- 2018-08-14 CL CL2018002334A patent/CL2018002334A1/es unknown
-
2019
- 2019-06-12 US US16/439,317 patent/US20200149047A1/en not_active Abandoned
- 2019-09-04 HR HRP20191600 patent/HRP20191600T1/hr unknown
- 2019-11-07 JP JP2019201990A patent/JP7158363B2/ja active Active
-
2020
- 2020-03-11 AU AU2020201763A patent/AU2020201763A1/en not_active Abandoned
-
2021
- 2021-09-02 US US17/465,035 patent/US11926830B2/en active Active
-
2022
- 2022-01-28 JP JP2022011551A patent/JP7297112B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225638A1 (zh) | 補體因子b的調節劑 | |
HRP20182004T1 (hr) | Tetrahidropiridopirazini modulatori gpr6 | |
HRP20171168T4 (hr) | Modulatori p2x7 | |
HK1254111A1 (zh) | P2x7調節劑 | |
HK1232216A1 (zh) | 調製器 | |
HK1218651A1 (zh) | 調節劑 | |
EP2968296A4 (en) | MODULATORS OF GAMMA-SECRETASE | |
SG11201604839XA (en) | Wnt pathway modulators | |
TWI560487B (en) | Electro-optical modulator | |
GB201321601D0 (en) | Modulator | |
GB201312727D0 (en) | Modulators | |
GB201318298D0 (en) | Modulators | |
GB201317988D0 (en) | Modulators | |
GB201304473D0 (en) | Modulators | |
GB201306008D0 (en) | Modulators of miRNA-184 mediated pathways | |
GB201314051D0 (en) | Novel DRAK modulators |